Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aligos Therapeutics Inc (NQ: ALGS ) 0.5037 +0.0107 (+2.17%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 147,198 Open 0.4900 Bid (Size) 0.5100 (4) Ask (Size) 0.5310 (50) Prev. Close 0.4930 Today's Range 0.4850 - 0.5190 52wk Range 0.3482 - 1.200 Shares Outstanding 42,940,089 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB July 10, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 June 05, 2024 From Aligos Therapeutics Via GlobeNewswire Performance YTD -29.00% -29.00% 1 Month +11.69% +11.69% 3 Month -37.12% -37.12% 6 Month -26.02% -26.02% 1 Year -45.25% -45.25% More News Read More Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 May 22, 2024 From Aligos Therapeutics Via GlobeNewswire Recap: Aligos Therapeutics Q4 Earnings March 12, 2024 Via Benzinga Aligos Therapeutics Earnings Preview March 11, 2024 Via Benzinga Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH May 21, 2024 From Aligos Therapeutics Via GlobeNewswire ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024 May 07, 2024 Via InvestorPlace Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results May 07, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 April 30, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 April 09, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects April 03, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies March 27, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects March 18, 2024 From Aligos Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session March 15, 2024 Via Benzinga Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results March 12, 2024 From Aligos Therapeutics Via GlobeNewswire Earnings Scheduled For March 12, 2024 March 12, 2024 Via Benzinga Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 March 05, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 February 26, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 February 20, 2024 From Aligos Therapeutics Via GlobeNewswire Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments February 13, 2024 From Aligos Therapeutics Via GlobeNewswire Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket December 08, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session December 07, 2023 Via Benzinga Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) December 07, 2023 From Aligos Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.